NCT02699606View on ClinicalTrials.gov

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 8, 2016

Primary Completion Date

October 12, 2021

Study Completion Date

March 15, 2024

Conditions
Neoplasm
Interventions
DRUG

Erdafitinib

Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.

Trial Locations (6)

Unknown

Beijing

Harbin

Nanjing

Seoul

Kaohsiung City

Tainan City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02699606 - A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma | Biotech Hunter | Biotech Hunter